Roivant’s longer-term colitis data set a bar in emerging TL1A class

New Phase IIb ulcerative colitis data showing rising remission rates over time suggest a molecule from Roivant and Pfizer has exceeded efficacy expectations, driving a gain in market cap of about $334 million and setting a bar for others in the class.

Management at Roivant Sciences Ltd. (NASDAQ:ROIV) had hoped that patients receiving TL1A inhibitor RVT-3101 through the later months of a 56-week study period would maintain an efficacy level seen in the TUSCANY-2 study’s initial 14-week induction phase. Data announced Thursday showed that in the study’s chronic phase, remission rates rose, along with rates of endoscopically observed improvement...